Long acting GLP-1 receptor agonist (injectable)
Taspoglutide 10 mg injection every 2 weeks
TASP_SC_10MG_Q2W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.65 (0.01 to 51.31) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.16 (1.95 to 8.77) | 0.32 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.04 (1.56 to 13.99) | 0.31 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.35 (0.89 to 5.75) | 0.34 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.86 (0.05 to 14.25) | 0.47 |